Compare ADMA Biologics Inc (ADMA) vs Invesco S&P 500 Low Volatility ETF (SPLV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ADMA Biologics Inc vs Invesco S&P 500 Low Volatility ETF — how do they compare? ADMA Biologics Inc trades at $9.87 (market cap $2.22B), while Invesco S&P 500 Low Volatility ETF trades at $75.78. The key difference: Invesco S&P 500 Low Volatility ETF is trading nearer its 52-week high, ADMA Biologics Inc nearer its low. Which is the better fit depends on your goals.
| ADMA | SPLV | |
|---|---|---|
Market Cap | $2.22B | — |
Sector | Health | — |
52-Week High | $20.38 | $77.97 |
52-Week Low | $7.60 | $70.30 |
Enterprise Value | $2.29B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.87, up 1.23% today, with a bullish technical signal supported by moving averages. The company reported strong 2025 fundamentals, including $510.17M revenue, 32.98% net income margin, and robust profitability metrics like 41.9% ROE. However, recent Q1 and Q2 2026 earnings missed expectations, and the stock faces significant negative sentiment due to multiple class-action lawsuits alleging securities fraud, with deadlines in August 2026.
The outlook is mixed: strong fundamentals and an 88.89% analyst buy rating support upside, but legal overhangs and earnings misses pose near-term risks. Investors should weigh solid financial health against potential volatility from litigation outcomes and execution consistency.
SPLV trades at $75.63, down slightly by 0.09% with a bullish technical signal supported by moving averages. The ETF maintains quarterly dividend payments of $0.14 and shows strong institutional interest amid market volatility concerns. Recent news highlights growing investor focus on low-volatility strategies as geopolitical tensions and AI bubble fears drive demand for stability-oriented investments.
The outlook remains positive as low-volatility ETFs gain traction during uncertain market conditions. Key opportunities include defensive positioning and consistent dividend income, while risks center on potential underperformance during strong bull markets and concentration in specific sectors. The ETF's historical resilience during downturns supports its defensive appeal.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Invesco S&P 500 Low Volatility ETF
The fund generally will invest at least 90% of its total assets in the securities that comprise the underlying index. Strictly in accordance with its guidelines and mandated procedures, S&P Dow Jones Indices LLC (the "index Provider") compiles, maintains and calculates the underlying index, which is designed to measure the performance of the 100 least volatile constituents of the S&P 500 ® Index over the past 12 months as determined by the index Provider.
Read more on SPLV →
